Evonik drives sustainable biosurfactant revolution with inauguration of new facility in Slovakia
First facility worldwide to manufacture industrial-scale rhamnolipid biosurfactants
Evonik has officially inaugurated its new sustainable biosurfactant plant together with key customers in Slovakia. The triple-digit million-euro facility is the first worldwide to manufacture industrial-scale quantities of rhamnolipid biosurfactants. These exceptionally high-quality, sustainable biosurfactants are already transforming the cleaning, beauty and personal care industries and have huge potential in many other applications.
“We go beyond to create entirely new solutions and drive the sustainable transformation across multiple industries. Our leadership, based on systems thinking and a shared vision with our customers, has made this scalable action possible,” said Christian Kullmann, CEO of Evonik.
Evonik has been leading the development of industrial-scale biosurfactants with its IP-protected, fermentation-based process for rhamnolipid production. Rhamnolipids are made from renewable corn feedstocks using a biotechnological process. This yields a high-performing, non-toxic, biodegradable biosurfactant. Rhamnolipids are increasingly in demand because they provide a sustainable alternative to surfactants based on fossil sources or tropical oils.
By 2030, Evonik aims to have invested more than €3 billion in Next Generation Solutions – products with superior sustainability benefits. One example is the biosurfactant technology platform that Evonik is building to serve diverse industries.
Evonik’s expertise in biotechnology is spearheaded by its life sciences division, Nutrition & Care. Driven by sustainability, the division is using innovative biosolutions to address the challenges of biocircular care through closed-loop carbon systems, while maintaining high functionality and preserving biodiversity. In addition to biosurfactants, Nutrition & Care’s biosolutions include biotech actives, cell culture solutions and nucleic acid-based medicines.
The new facility is based at Evonik Fermas, the company’s site in Slovenská Ľupča, Slovakia. Biotechnology capabilities at the site have been built up over many decades, making it the logical choice for the first industrial-scale rhamnolipid production facility. This reinforces the position of Evonik Fermas as a biotechnology scale-up and launch platform for Evonik.
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.